Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%

The Indian pharma sector is highly sensitive to US regulatory and pricing policies, as the US is a major export market. Potential tariffs directly threaten revenue and profitability for many Indian drug manufacturers.

Maintain a bearish bias on Indian pharma stocks; look for shorting opportunities or avoid fresh long positions until tariff uncertainty subsides.

For Indian markets, this story mainly matters for SUNPHARMA, and the Pharmaceuticals pocket. The current signal is bearish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Explicitly mentioned as plunging up to 6% due to tariff concerns. The article states 'other pharma stocks plunge up to 6%', indicating a sector-wide negative impact. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Pharma stocks fell after reports of potential Trump administration tariffs.
• •Tariffs could be up to 100% on drugmakers not ensuring low prices in the US.
• •Concerns raised over increased costs and supply chain disruptions.
• •Sun Pharma and other pharma stocks plunged up to 6%.
• •Risk flag: Uncertainty regarding the actual implementation and scope of tariffs.